Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
13th August 2025 Uncategorised 0
Promising results support global submissions and priority review by US FDA

More: Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Source: News
